购物车
- 全部删除
- 您的购物车当前为空
NDMC101 是有效的破骨细胞形成抑制剂,通过下调 NFATc1 调控基因表达抑制破骨细胞分化。它与 DPP4底物相似,通过抑制DPP4抑制早期 T 细胞激活。它能够用于骨疾病的研究,如类风湿关节炎、滑膜炎等。
为众多的药物研发团队赋能,
让新药发现更简单!
NDMC101 是有效的破骨细胞形成抑制剂,通过下调 NFATc1 调控基因表达抑制破骨细胞分化。它与 DPP4底物相似,通过抑制DPP4抑制早期 T 细胞激活。它能够用于骨疾病的研究,如类风湿关节炎、滑膜炎等。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 148 | 现货 | |
5 mg | ¥ 347 | 现货 | |
10 mg | ¥ 588 | 现货 | |
25 mg | ¥ 1,150 | 现货 | |
50 mg | ¥ 1,990 | 现货 | |
100 mg | ¥ 2,920 | 现货 | |
200 mg | ¥ 3,970 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 333 | 现货 |
产品描述 | NDMC101 is an inhibitor of dipeptidyl peptidase-IV activity in human T cells and exhibits immunomodulatory effects. It also acts as a novel inhibitor of NFATc1 and NF-κB activity. |
体外活性 | NDMC101在RAW264.7和骨髓巨噬细胞(BMMs)中明显抑制了RANKL诱导的TRAP+多核细胞形成。此外,骨吸收活性测定表明,NDMC101显著降低了成熟破骨细胞的骨吸收活性[1]。 |
体内活性 | 在CIA小鼠中,口服NDMC101能够降低关节炎指数并缓解骨侵蚀。在62.5 mg/kg的较高剂量下,这些小鼠的血清TNF-α和IL-1β浓度显著下降[1]。 |
细胞实验 | Differentiation into osteoclast-like cells was examined by tartrate-resistant acid phosphatase (TRAP) staining and expression of osteoclast differentiation markers[1]. |
动物实验 | Collagen-induced arthritis (CIA) mice were administered test articles by gavages to assess its efficacy.?Then clinical, histological, and biochemical parameters were assessed to determine the effects of N-(4-chloro-2-fluorophenyl)-2-hydroxybenzamide (NDMC101) on synovial inflammation and bone erosion by hematoxlin and eosin staining and Enzyme-linked immunosorbent assay (ELISA)[1]. |
分子量 | 265.67 |
分子式 | C13H9ClFNO2 |
CAS No. | 1308631-40-4 |
Smiles | Oc1ccccc1C(=O)Nc1ccc(Cl)cc1F |
密度 | 1.452 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
溶解度信息 | DMSO: 11 mg/mL (41.4 mM) | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容